Login to Your Account



Cephalon's $590M Mepha Buyout Expands Footprint

By Trista Morrison


Tuesday, February 2, 2010
The experts at Ernst & Young previously predicted pharma's acquisition tastes in 2010 would run toward international firms, particularly those that provide a toehold in emerging markets, and players in the fragmented branded generics space, which is ripe for consolidation. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription